Compare WTFCN & BCTXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Wintrust Financial Corporation Depositary Shares Each Representing a 1/1000th Interest in a Share of 7.875% Fixed-Rate Reset Non-Cumulative Perpetual Preferred StocK
| Metric | WTFCN | BCTXL |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | 5902 | 4 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | WTFCN | BCTXL |
|---|---|---|
| Price | $26.40 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.5K | ★ 29.6K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.55 | $0.77 |
| 52 Week High | $27.31 | $1.40 |
| Indicator | WTFCN | BCTXL |
|---|---|---|
| Relative Strength Index (RSI) | 59.22 | 44.80 |
| Support Level | $26.15 | $0.92 |
| Resistance Level | $26.36 | $1.25 |
| Average True Range (ATR) | 0.15 | 0.10 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 89.38 | 46.49 |
Wintrust Financial Corp is a financial holding company that provides community-oriented, personal, and commercial banking services to customers generally located in the Chicago metropolitan area, southern Wisconsin, northwest Indiana, and western Michigan. The company provides specialty finance services, including financing for the payment of property and casualty insurance premiums and life insurance premiums, and wealth management services to customers in its market area. Its operations consist of three primary segments: community banking, specialty finance, and wealth management. The company generates the majority of its revenue from the community banking segment.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.